
About this episode
I sit down with Dr. Matthias Kloor, Acting Medical Director Applied Tumor Biology at Heidelberg University. We discuss the thought process followed by the hurdles faced in trying to get a Lynch Syndrome vaccine, through the phases, to potentially the proverbial bedside. We discussed collaboration with the NCI in bringing this and other projects to market. We also talk about the European Hereditary Tumor Group, whose conference this year is also in Heidelberg. EHTG is a great group, one that has embraced the advocacy community, similar to CGAIGC and InSIGHT.
Get every episode summarized
Each time AliveandKick'n the podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from AliveandKick'n the podcast

AliveAndKickn Podcast - Hanna Lombardi
AliveandKick'n the podcast

AliveAndKickn Podcast - Stef Alastre
AliveandKick'n the podcast

AliveAndKickn Podcast - Dr Mev Dominguez
AliveandKick'n the podcast

AliveAndKickn Podcast - Laura Schneebaum
AliveandKick'n the podcast